Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan

被引：0
|
作者：
Gonzalez-Baron, M. [1 ]
Blanco, M. [1 ]
Feliu, J. [1 ]
Gomez, C. [1 ]
Casado, E. [1 ]
Castro, J. [1 ]
Belda-Iniesta, C. [1 ]
Garrido, M. [1 ]
Aguayo, C. [1 ]
Campos, M. A. [1 ]
机构：
[1] Hosp La Paz, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14600
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [32] Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Lenz, Heinz-Josef
    Van Cutsem, Eric
    Khambata-Ford, Shirin
    Mayer, Robert J.
    Gold, Philip
    Stella, Philip
    Mirtsching, Barry
    Cohn, Allen L.
    Pippas, Andrew W.
    Azarnia, Nozar
    Tsuchihashi, Zenta
    Mauro, David J.
    Rowinsky, Eric K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4914 - 4921
  • [33] Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer.
    Saltz, LB
    Lenz, HJ
    Hochster, H
    Wadler, S
    Hoff, P
    Kemeny, N
    Hollywood, E
    Gonen, M
    Wetherbee, S
    Chen, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 248S - 248S
  • [34] The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients
    Sohn, Byeong Seok
    Kim, Tae Won
    Lee, Jae-Lyun
    Ryu, Min-Hee
    Chang, Heung Moon
    Kang, Yoon-Koo
    Park, Hyo Suk
    Na, Young-Soon
    Jang, Se Jin
    Kim, Jin Cheon
    Lee, Jung Shin
    ONCOLOGY, 2009, 77 (3-4) : 224 - 230
  • [35] EFFECT OF ENZASTAURIN IN PATIENTS WITH COLORECTAL CANCER TREATED WITH IRINOTECAN PLUS CETUXIMAB
    Iqbal, S.
    Miller, C.
    Figueroa, J.
    Hossain, A.
    Nicol, S.
    Mulcahy, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 66 - 66
  • [36] Pharmacokinetics of Irinotecan in Combination with Biweekly Cetuximab in Patients with Advanced Colorectal Cancer
    Czejka, Martin
    Gruenberger, Birgit
    Kiss, Andreas
    Farkouh, Andre
    Schueller, Johannes
    ANTICANCER RESEARCH, 2010, 30 (06) : 2355 - 2360
  • [37] Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study
    Buzaid, Antonio C.
    Mathias, Clarissa de Cerqueira
    Perazzo, Florencia
    Simon, Sergio D.
    Fein, Luis
    Hidalgo, Jorge
    Murad, Andre M.
    Esser, Regina
    Senger, Stefanie
    Lerzo, Guillermo
    CLINICAL COLORECTAL CANCER, 2010, 9 (05) : 282 - 289
  • [38] Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Ryu, Min-Hee
    Chang, Heung Moon
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    ANNALS OF ONCOLOGY, 2006, 17 : 131 - 131
  • [39] The impact of the introduction of irinotecan and oxaliplatin on the outcome of patients with advanced colorectal cancer
    Lelli, G.
    Carandina, I.
    Urbini, B.
    Guarino, S.
    Modonesi, C.
    Pedriali, M.
    JOURNAL OF CHEMOTHERAPY, 2007, 19 (05) : 590 - 595
  • [40] The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer
    Khayat, D
    Gil-Delgado, M
    Antoine, EC
    Nizri, D
    Bastian, G
    ONCOLOGY-NEW YORK, 2001, 15 (04): : 415 - 429
12345